Skip to main content

Month: March 2025

Melcor Developments announces results for 2024, declares $0.11 per share dividend

EDMONTON, Alberta, March 13, 2025 (GLOBE NEWSWIRE) — Melcor Developments Ltd. (TSX: MRD), an Alberta-based real estate development and asset management company, today reported results for the fourth quarter and year ended December 31, 2024. The annual Management Discussion & Analysis (MD&A) and Condensed Interim Financial Statements are available on our website (www.melcor.ca) under Investors, or on SEDAR+ (www.sedarplus.ca). Timothy Melton, Melcor’s Executive Chair and Chief Executive Officer, commented: “We are pleased to present Melcor’s annual results for 2024. Our Canadian Land division benefited from sustained migration into Alberta, fueling steady demand for residential shelter. Strong sales in our Edmonton and Calgary regions contributed to a very good year, with revenues up 12.6% and earnings up 10.8%...

Continue reading

Blue Moon Announces Resumption of Trading, Graduation to Tier 1 on the TSX Venture Exchange and Completion of Share Consolidation Following Transformational Acquisitions

TORONTO, March 13, 2025 (GLOBE NEWSWIRE) — Blue Moon Metals Inc. (“Blue Moon” or the “Company”) (TSXV: MOON) is pleased to announce that its common shares (the “Blue Moon Shares”) will resume trading on the TSX Venture Exchange (“TSXV”) at the market open on Friday, March 14, 2025. Upon resumption of trading, the graduation of the Company from Tier 2 to Tier 1 issuer status on the TSXV, and the consolidation of the Blue Moon Shares, previously announced on March 3, 2025 and March 10, 2025, respectively, will be effected (the “Consolidation”). Trading of the Blue Moon Shares was halted on November 27, 2024 in connection with the announcement of the acquisitions of Nussir ASA and Nye Sulitjelma Gruver AS, which closed on February 26, 2025. The Company also announced on March 10, 2025, that it acquired all the shares in Repparfjord...

Continue reading

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL. ○ UCART20x22 Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025. ○ AstraZeneca partnership: R&D activities ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorder. ○ Cash position of $264 million as of December 31, 20241 provides runway into mid-2027. ○ Conference call March 14, 2025 at 8:00 am ET / 1:00 pm CET. NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) — Cellectis (the “Company”)...

Continue reading

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™ NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) — Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025. “We look forward to the upcoming shareholder vote on our pending merger with Cyclo Therapeutics (Nasdaq: CYTH) later this month and anticipate closing promptly post shareholder approvals. Upon closing, the Company’s strategic focus will be on its lead clinical asset, Trappsol® Cyclo™,” said Bill Conkling, CEO of Rafael Holdings. Bill added, “We are encouraged by the preliminary results presented at the 21st...

Continue reading

Nokia has published its Nokia in 2024 Annual Report and filed its Annual Report on Form 20-F for 2024

Nokia CorporationStock Exchange Release13 March 2025 at 23:30 EET Nokia has published its Nokia in 2024 Annual Report and filed its Annual Report on Form 20-F for 2024 Espoo, Finland – Nokia has today published its Nokia in 2024 Annual Report, which includes audited financial statements, the annual review by the Board of Directors, including the Sustainability Statement, Nokia’s corporate governance statement and the Remuneration Report for the governing bodies for 2024. Additionally, Nokia has filed its Annual Report on Form 20-F for 2024 with the U.S. Securities and Exchange Commission. The Nokia in 2024 Annual Report and the Annual Report on Form 20-F will be available in PDF format at www.nokia.com/financials. The corporate governance statement will be available also at www.nokia.com/about-us/company/leadership-and-governance and...

Continue reading

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2024

MISSISSAUGA, Ontario, March 13, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2024. Key highlights include:(CAD) Q4 2024   % Change  vs. Q4 2023 FY 2024  % Change  vs. FY 2023 Canadian Pharma Sales 8,546,451  +7 % 32,931,149  +11 % International Pharma Sales 176,734  +223 % 929,975  -11 %Legacy Business Sales 73,499  -68 % 1,169,773  +18 %Total Company Sales 8,796,684  +6 % 35,030,897  +11 %EBITDA1 2,241,112  +36 % 9,343,012  +18 %Net Income After Taxes (NIAT) 1,613,194  +11 % 7,270,104  +13 %Fully Diluted EPS 0.14  +17 %  0.62  +16 %             Return on Equity for FY 2024 was 21% as compared to 19% for FY 2023 During FY 2024, repurchased for cancellation a total of 492,300...

Continue reading

Atlanticus Reports Fourth Quarter and Full Year 2024 Financial Results

Fourth Quarter 2024 net margin growth of 28.0% over prior year, with 3.7 million accounts served (1) ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) — Atlanticus Holdings Corporation (NASDAQ: ATLC) (Atlanticus, the Company, we, our or us), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced its financial results for the fourth quarter and full year ended December 31, 2024. An accompanying earnings presentation is available in the Investors section of the Company’s website at www.atlanticus.com or by clicking here. Financial and Operating Highlights Fourth Quarter 2024 Highlights (all comparisons to the Fourth Quarter 2023)Managed receivables2 increased 13.0% to $2.7 billion Total operating revenue and other...

Continue reading

Mattr Announces Fourth Quarter and Full Year 2024 Results

TORONTO, March 13, 2025 (GLOBE NEWSWIRE) — Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR) reported today its operational and financial results for the three and twelve months ended December 31, 2024. This press release should be read in conjunction with the Company’s Management Discussion and Analysis (“MD&A”) and audited consolidated financial statements for the years ended December 31, 2024 and 20231, which are available on the Company’s website and at www.sedarplus.com. Highlights include1:On a consolidated basis (including Continuing Operations and Discontinued Operations), Mattr reported full year 2024 revenue of $960 million, net loss of $4 million, Adjusted EBITDA2 of $131 million, diluted (Loss) Earnings Per Share (“EPS”) of (0.06) and diluted Adjusted EPS2 of $0.69; Full year Continuing Operations revenue was...

Continue reading

Priority Income Fund Announces 13.0% Annualized Total Cash Distribution Rate (on Class R Offering Price) with “Bonus” and “Base” Common Shareholder Distributions for March 2025 through May 2025

NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) — Priority Income Fund, Inc. (“Priority Income Fund” or the “Fund”) announced today that the Fund’s Board of Directors has declared monthly cash “base” and “bonus” common shareholder distributions for March 2025, April 2025 and May 2025. The annualized total cash distribution is $1.34016 per share (13.0% annualized rate for Class R and 14.0% annualized rate for Class I), for distributions with record dates between March 13, 2025 and May 5, 2025 based on the current Class R offering price of $10.29 per common share and the current Class I offering price of $9.60 per common share. The cash “base” distribution will have monthly record dates and will be payable monthly to common stockholders of record at the close of business each month. These declared distributions equal a weekly cash amount...

Continue reading

Iridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025

MOUNTAIN VIEW, Calif., March 13, 2025 (GLOBE NEWSWIRE) — Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the fourth quarter and full year 2024 and provide a business update after the close of trading on Thursday, March 27, 2025. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 5685253. A live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com. About Iridex Corporation Iridex...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.